JP2016504416A5 - - Google Patents

Download PDF

Info

Publication number
JP2016504416A5
JP2016504416A5 JP2015552725A JP2015552725A JP2016504416A5 JP 2016504416 A5 JP2016504416 A5 JP 2016504416A5 JP 2015552725 A JP2015552725 A JP 2015552725A JP 2015552725 A JP2015552725 A JP 2015552725A JP 2016504416 A5 JP2016504416 A5 JP 2016504416A5
Authority
JP
Japan
Prior art keywords
antigen
binding fragment
antibody
beta
pdgfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015552725A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016504416A (ja
JP6367233B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/010395 external-priority patent/WO2014109999A1/en
Publication of JP2016504416A publication Critical patent/JP2016504416A/ja
Publication of JP2016504416A5 publication Critical patent/JP2016504416A5/ja
Application granted granted Critical
Publication of JP6367233B2 publication Critical patent/JP6367233B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015552725A 2013-01-09 2014-01-07 抗pdgfr−ベータ抗体及びそれらの使用 Active JP6367233B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361750437P 2013-01-09 2013-01-09
US61/750,437 2013-01-09
US201361863452P 2013-08-08 2013-08-08
US61/863,452 2013-08-08
US201361909421P 2013-11-27 2013-11-27
US61/909,421 2013-11-27
PCT/US2014/010395 WO2014109999A1 (en) 2013-01-09 2014-01-07 ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF

Publications (3)

Publication Number Publication Date
JP2016504416A JP2016504416A (ja) 2016-02-12
JP2016504416A5 true JP2016504416A5 (enExample) 2017-02-09
JP6367233B2 JP6367233B2 (ja) 2018-08-01

Family

ID=50002880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015552725A Active JP6367233B2 (ja) 2013-01-09 2014-01-07 抗pdgfr−ベータ抗体及びそれらの使用

Country Status (21)

Country Link
US (3) US9265827B2 (enExample)
EP (1) EP2943218B1 (enExample)
JP (1) JP6367233B2 (enExample)
KR (1) KR102146692B1 (enExample)
CN (1) CN104936614B (enExample)
AU (3) AU2014205641B2 (enExample)
BR (1) BR112015016312B1 (enExample)
CA (1) CA2897383C (enExample)
CL (2) CL2015001924A1 (enExample)
EA (2) EA031049B1 (enExample)
IL (2) IL239552B (enExample)
JO (1) JO3405B1 (enExample)
MX (1) MX363635B (enExample)
MY (1) MY169165A (enExample)
NZ (1) NZ709683A (enExample)
PH (1) PH12015501493A1 (enExample)
SG (2) SG10201701308VA (enExample)
TW (1) TWI647239B (enExample)
UY (1) UY35258A (enExample)
WO (1) WO2014109999A1 (enExample)
ZA (1) ZA201504537B (enExample)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
EA201690212A8 (ru) 2013-07-12 2016-08-31 Офтотек Корпорейшн Способы лечения или профилактики офтальмологических патологических состояний
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
RU2723940C2 (ru) 2014-03-21 2020-06-18 Экс-Боди, Инк. Биспецифические антигенсвязывающие полипептиды
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP2017537896A (ja) 2014-11-10 2017-12-21 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 二重特異性抗体及び眼科に使用する方法
BR112017009790A2 (pt) 2014-11-10 2017-12-19 Hoffmann La Roche anticorpos direcionados ao anti-ang2 e métodos de uso
BR112017009792A2 (pt) * 2014-11-10 2018-02-27 Hoffmann La Roche anticorpos anti-pdgf-b e métodos de uso
AU2015345320A1 (en) 2014-11-10 2017-04-06 F. Hoffmann-La Roche Ag Anti-IL-1beta antibodies and methods of use
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
EA201791768A1 (ru) * 2015-02-06 2018-07-31 КАДМОН КОРПОРЕЙШН, ЭлЭлСи Иммуномодулирующие агенты
RU2712623C2 (ru) * 2015-03-31 2020-01-30 Илдонг Фарм. Ко., Лтд. Фармацевтическая композиция для предотвращения и лечения заболеваний глаз, содержащая в качестве активного ингредиента белок слияния, в котором слиты проникающий в ткань пептид и препарат против фактора роста эндотелия сосудов
RU2749674C2 (ru) 2015-07-29 2021-06-16 Аллерган, Инк. Антитела против ang-2, содержащие только тяжелую цепь
TWI899515B (zh) 2015-08-04 2025-10-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
EA201891164A1 (ru) 2015-12-16 2018-11-30 Ридженерон Фармасьютикалз, Инк. Композиции и способы получения белковых микрочастиц
BR112018013407A2 (en) 2015-12-30 2018-12-18 Kodiak Sciences Inc. antibodies and conjugates thereof
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
CA3029332A1 (en) * 2016-07-01 2018-01-04 Ludwig Institute For Cancer Research Ltd Methods and compositions for pdgf-cc inhibition
MX2019000935A (es) 2016-08-16 2019-07-04 Regeneron Pharma Metodos para cuantificar anticuerpos individuales de una mezcla.
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CN109021104B (zh) * 2017-06-12 2022-08-12 上海睿智化学研究有限公司 一种抗人血小板衍生生长因子β受体的抗体及其应用
CN114075269A (zh) 2017-07-06 2022-02-22 菲仕兰坎皮纳荷兰私人有限公司 用于制备糖蛋白的细胞培养工艺
CN111479618B (zh) 2017-12-22 2022-08-02 瑞泽恩制药公司 用于表征药物产品杂质的系统和方法
KR20200115485A (ko) 2018-01-31 2020-10-07 리제너론 파마슈티칼스 인코포레이티드 약물 생성물 불순물을 특성화하기 위한 시스템 및 방법
TWI786265B (zh) 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
US12460270B2 (en) 2018-02-28 2025-11-04 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
BR112020015291B1 (pt) 2018-03-19 2023-09-26 Regeneron Pharmaceuticals, Inc Tampão de amostra de eletroforese aquoso, método para identificar contaminantes ou impurezas em uma amostra de fármaco proteico, e, kit
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
GB201806918D0 (en) * 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
CN108586611B (zh) * 2018-04-28 2021-01-26 暨南大学 重组全人源抗破伤风毒素单克隆抗体
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
KR20210053816A (ko) 2018-08-30 2021-05-12 리제너론 파마슈티칼스 인코포레이티드 단백질 복합체를 특성화하기 위한 방법
JP7119225B2 (ja) * 2018-10-05 2022-08-16 ソウル大学校産学協力団 Pdgf受容体に対する抗体およびその用途
IL284471B2 (en) 2019-01-16 2025-01-01 Regeneron Pharma Methods for identifying free thiols in proteins
US12552866B2 (en) 2019-03-08 2026-02-17 Linxis B.V. Internalizing binding molecules targeting receptors involved in cell proliferation or in cell differentiation
WO2020225147A1 (en) 2019-05-03 2020-11-12 Singapore Health Services Pte. Ltd. Treatment and prevention of metabolic diseases
EP3969908A1 (en) 2019-05-13 2022-03-23 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
KR20250051157A (ko) 2019-06-05 2025-04-16 리제너론 파아마슈티컬스, 인크. 정밀 투여량 전달을 위한 디바이스 및 방법
EP4653865A3 (en) 2019-09-24 2026-02-18 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
MX2022006236A (es) 2019-11-25 2022-06-22 Regeneron Pharma Formulaciones de liberacion sostenida con emulsiones no acuosas.
US20230090552A1 (en) 2020-01-08 2023-03-23 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
KR102544013B1 (ko) 2020-01-21 2023-06-19 리제너론 파마슈티칼스 인코포레이티드 당질화된 단백질의 전기영동을 위한 탈당질화 방법
KR20220140551A (ko) * 2020-02-07 2022-10-18 바이오리온 테크놀러지스 비.브이. 혈소판 유래 성장 인자 수용체(pdgfr) 항체, 이의 컨쥬게이트, 조성물 및 용도
CA3192999A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
JP2023541934A (ja) * 2020-09-16 2023-10-04 リンクシス ベスローテン フェンノートシャップ 内在化結合分子
EP4251128A1 (en) 2020-11-25 2023-10-04 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
WO2022133135A1 (en) 2020-12-17 2022-06-23 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
CN116761880A (zh) 2021-01-20 2023-09-15 瑞泽恩制药公司 改进细胞培养物中的蛋白质滴度的方法
JP2024505195A (ja) * 2021-01-25 2024-02-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗pdgf-b抗体及び肺動脈高血圧症(pah)を治療するための使用方法
CA3207883A1 (en) 2021-03-03 2022-09-09 Xiaobin Xu Systems and methods for quantifying and modifying protein viscosity
US20220309215A1 (en) 2021-03-26 2022-09-29 Regeneron Pharmaceuticals, Inc. Methods and systems for developing mixing protocols
AU2022286340A1 (en) 2021-06-01 2024-01-04 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
WO2023039457A1 (en) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins
AU2022348521A1 (en) 2021-09-20 2024-04-04 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
CN118076894A (zh) 2021-10-07 2024-05-24 里珍纳龙药品有限公司 pH建模和控制的系统及方法
KR20240090312A (ko) 2021-10-07 2024-06-21 리제너론 파아마슈티컬스, 인크. Ph 미터 보정 및 교정
KR20240097864A (ko) 2021-10-26 2024-06-27 리제너론 파마슈티칼스 인코포레이티드 상이한 온도에서 실험실 용수를 생성하고 실험실 용수를 분배하는 시스템 및 방법
CA3245647A1 (en) 2022-03-18 2023-09-21 Regeneron Pharmaceuticals, Inc. METHODS AND SYSTEMS FOR ANALYZING POLYPEPTIDE VARIANTS
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
TW202435942A (zh) 2022-12-16 2024-09-16 美商里珍納龍藥品有限公司 評估層析管柱完整性的方法及系統
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
TW202445126A (zh) 2023-01-25 2024-11-16 美商再生元醫藥公司 基於質譜法之體內共表現抗體之表徵
TW202445138A (zh) 2023-02-01 2024-11-16 美商再生元醫藥公司 用於生物巨分子分析之具質譜法的不對稱流場流分離
WO2024178213A2 (en) 2023-02-22 2024-08-29 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
TW202508625A (zh) 2023-05-01 2025-03-01 美商再生元醫藥公司 使用苯酚或苯甲醇之多劑量抗體藥物產品
US20250086164A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2025064403A2 (en) 2023-09-18 2025-03-27 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
US20250109905A1 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
US20250129117A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
US20250145662A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
CN118440214B (zh) * 2024-04-02 2025-01-28 山东大学 一种靶向PDGFRβ的嵌合抗原受体、CAR-T细胞及应用
WO2025259840A1 (en) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Methods and systems for scaled chromatography
WO2026025028A1 (en) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Methods of making ultra-high concentrated protein formulations using lyophilization

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DK0584082T3 (da) 1991-01-31 2000-10-16 Univ California Domæner i den ekstracellulære region af humane blodpladeafledte vækstfaktorreceptorpolypeptider
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US20020009443A1 (en) * 1991-12-02 2002-01-24 Vanitha Ramakrishman Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
DE69233125T2 (de) * 1991-12-02 2004-04-22 Millennium Pharmaceuticals, Inc., South San Francisco Inhibitorische immunglobulin-polypeptide gegen den pdgf beta-rezeptor
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5620687A (en) 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
AU2004268614C1 (en) 2003-08-27 2010-10-28 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
RS52176B (sr) 2006-06-02 2012-08-31 Regeneron Pharmaceuticals Inc. Antitela visokog afiniteta prema humanom il-6 receptoru
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
KR101136262B1 (ko) * 2007-04-17 2012-07-05 임클론 엘엘씨 PDGFRβ-특이적 억제제
AU2008262384B9 (en) 2007-06-05 2014-11-27 Yale University Inhibitors of receptor tyrosine kinases and methods of use thereof
JP5303557B2 (ja) 2007-08-22 2013-10-02 アイアールエム・リミテッド・ライアビリティ・カンパニー キナーゼ阻害剤である2−ヘテロアリールアミノ−ピリミジン誘導体
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
SI2274008T1 (sl) * 2008-03-27 2014-08-29 Zymogenetics, Inc. Sestavki in metode za zaviranje PDGFRBETA in VEGF-A
EP3028707A1 (en) 2009-05-01 2016-06-08 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
KR20200077622A (ko) 2011-01-13 2020-06-30 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
CN102250249A (zh) 2011-06-18 2011-11-23 常州亚当生物技术有限公司 一种抗VEGF/PDGFRbeta双特异性抗体及其应用

Similar Documents

Publication Publication Date Title
JP2016504416A5 (enExample)
JP6877500B2 (ja) TGF−βに特異的な抗体
RU2015121755A (ru) Антагонисты ил-6 и их применение
JP7695187B2 (ja) HPTP-β(VE-PTP)およびVEGFを標的にする多特異性抗体
JP2020515545A5 (enExample)
JP7107914B2 (ja) VE-PTP(HPTP-β)を標的化するヒト化モノクローナル抗体
JP2010528047A5 (enExample)
JP2017535285A5 (enExample)
RU2014113046A (ru) Профилактика и лечение патологических состояний глаз, вызванных комплементом
WO2008154251A4 (en) C3b antibodies and methods for the prevention and treatment of complement- associated disorders
JP2019515027A5 (enExample)
JP2020514376A5 (enExample)
JP6446560B2 (ja) VEGFA/Ang2化合物
RU2012107286A (ru) Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2
JP2011504872A5 (enExample)
JP2013528607A5 (enExample)
JP2019510078A5 (enExample)
JP2012165745A5 (enExample)
JP2018510617A5 (enExample)
JP2018093875A5 (enExample)
JP2018527327A5 (enExample)
JP2020536492A5 (enExample)
JP2017502023A (ja) 眼疾患を治療する組成物および方法
JP2021507677A5 (enExample)
HRP20251312T1 (hr) Poboljšana protutijela za il-6